编者按：
礼来亚洲基金（LAV）于2021年领投锐格医药B轮融资，在本次交易之前也是锐格最大的投资机构股东。以下新闻转载自锐格医药的PR。
正文：
9月30日，锐格医药（Regor Pharmaceuticals）宣布已与罗氏旗下公司基因泰克就下一代CDK抑制剂达成收购协议。
根据协议条款，基因泰克将以8.5亿美元的首付款收购锐格医药的下一代CDK抑制剂，锐格医药还有资格根据未来某些预定开发、监管和商业化里程碑的实现情况获得额外的现金付款。基因泰克将负责全球临床开发、生产和商业化工作。锐格医药将继续管理正在进行的两项I期试验直至完成。锐格还将推进其在肿瘤、代谢疾病和自身免疫方面的其他与此次交易无关的差异化资产。
锐格医药创始人兼首席执行官（CEO）邱夏杨博士说：“基因泰克完全有能力充分发挥这些新型疗法的潜力，使世界各地的乳腺癌患者受益。我们为迄今为止已有的强大数据感到自豪。我们期待为世界各地的患者带来更多创新疗法。”
预计该交易将于2024年第四季度完成。
Cambridge, Massachusetts, September 30, 2024 - Regor Pharmaceuticals (USA) ("Regor") has entered into a definitive purchase agreement whereby Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK inhibitors from Regor for the treatment of breast cancer.Under the terms of the agreement, Regor will receive an upfront cash payment of $850 million and is eligible to receive additional cash payments based on the achievement of certain predetermined development, regulatory and commercial milestones. Genentech will be responsible for clinical development, manufacturing and commercialization worldwide. Regor will continue to manage the two ongoing Phase 1 trials to their completion: Regor will also advance its other distinct assets, unrelated to this deal, in oncology, metabolic diseases and auto-immunity."Genentech is well-positioned to bring these novel therapeutics to their full potential to benefit patients with breast cancer around the world," said Xiayang Qiu, Ph.D., founder and CEO of Regor. " We are proud of the strong data we have generated to date. We look forward to bringing more innovative therapies to patients around the world."The proposed transaction is expected to close in the fourth quarter of 2024. The closing of the proposed transaction is subject to the satisfaction of customary closing conditions.BofA Securities, Inc. is acting as the exclusive financial advisor to Regor on this transaction, and Cohen, Tauber Spievack & Wagner PC and DLA Piper are its legal advisors.About Regor Pharmaceuticals (USA)Regor Pharmaceuticals (USA) is part of Regor Therapeutics Group, a clinical-stage biotechnology company developing innovative and clinically differentiated medicines to address large unmet needs in oncology, metabolism and auto-immunity. By leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, Regor Therapeutics Group has advanced over a dozen in-house discovered assets into various stages of preclinical and clinical development, validating its highly efficient ecosystem for accelerated discovery of innovative therapeutic agents. To learn more about Regor, please visit us at www.regor.com.
相关新闻：
欢迎关注：
<END>
*版权声明：本网站所转载的文章，均来自互联网，旨在传递更多信息。鉴于互联网的开放性和文章创作的复杂性，我们无法保证所转载的所有文章均已获得原作者的明确授权。如果您是原作者或拥有相关权益，请与我们联系，我们将立即删除未经授权的文章。本网站转载文章仅为方便读者查阅和了解相关信息，并不代表我们认同其观点和内容。读者应自行判断和鉴别转载文章的真实性、合法性和有效性。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
收藏
登录后参与评论